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Introduction
Cancer studies were focused mainly on tumor cells. It 
was 1889 when Paget proposed the “seed and soil” theory 
which suggests that neoplastic cells (seed) may only initiate 
tumor formation when in the context of a hospitable and 
supportive microenvironment (soil) [1]. But not that much 
time passed since researchers began to focus not only on 
neoplastic cells, but also on significant alterations in the 
surrounding stroma or tumor microenvironment. These al-
terations are now recognized as a critical element for breast 
cancer development and progression, as well as potential 
therapeutic targets. Different elements of the breast can-
cer microenvironment, such as immune cells, soluble fac-
tors and modified extracellular matrix, act together to stop 
effective antitumor immunity and stimulate breast cancer 
progression and metastasis. Stromal cells in the breast can-
cer microenvironment are characterized by molecular al-
terations and aberrant signaling pathways, some of which 
are prognostic factors for clinical outcome. Several new 
therapies targeting stromal components are in develop-
ment or undergoing clinical trials [2]. In this paper, there 
will be reviewed the key players of breast stroma and their 
role in tumorigenesis and cancer progression. However, a 
key question remains: which comes first, the dysfunction 
of epithelial cells or the dysfunction of their microenviron-
ment? [3].
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Abstract
Background: Cancer studies were focused mainly on tumor cells. But not that much time passed since researchers began to focus not only on neoplastic 
cells, but also on significant alterations in the surrounding stroma or tumor microenvironment. These alterations are now recognized as a critical element 
for breast cancer development and progression, as well as potential therapeutic targets. Different elements of the breast cancer microenvironment (such as 
immune cells, soluble factors and modified extracellular matrix) act together to stop effective antitumor immunity and stimulate breast cancer progression 
and metastasis. Stromal cells in the breast cancer microenvironment are characterized by molecular alterations and aberrant signaling pathways, some 
of which are prognostic factors for clinical outcome.
Conclusions: Tissue microenvironment has profound effects on the progression of cancer cells by its paracrine signaling. Molecular characterization of 
various cell types from the normal breast tissue, ductal carcinoma in situ and invasive breast tumor revealed significant changes in gene profile in all cell 
types during breast tumor progression. Microenvironment changes influence tumor progression as well as the efficacy of various cancer therapies. There 
is compelling evidence that the elements of tumor microenvironment respond to different stimuli and release distinct mediators, some antitumorigenic, 
while others protumorigenic activity. Each of the known players of breast stroma involved in tumorigenesis and cancer progression can be influenced 
and directed towards an “anticancer” state.
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Myoepithelial cells
The human breast represents a branching ductal system 
composed of two epithelial cell types: an inner layer of po-
larized epithelial cells and an outer layer of myoepithelial 
cells, separated from the stroma by a laminin-rich basement 
membrane (BM) [4]. BM is also composed of heparan sul-
fate proteoglycans, glycosaminoglycans and entactin. Myo-
epithelial cells are attached to luminal cells by desmosomes 
and to the BM by hemidesmosomes [5]. The myoepithelial 
cells are a fascinating type of cell, because they belong to 
two completely different types of tissues, namely the epi-
thelium and the mesenchyme, these having even a distinct 
embryonic origin. This two-sided nature is expressed not 
only by their position (on the one hand they are connected 
in typical manner with the secreting epithelium, whereas 
on the other hand they interact with the stroma and the 
basal membrane in the same way as smooth muscle cells), 
but also by their possession of potentialities of both tissues 
[6].
The branching ductal system ends with a terminal duc-
tal-lobular unit (TDLU), this being the basic functional and 
histopathological unit of the breast. The myoepithelial cells 
lining the ducts are spindle-shaped cells oriented parallel 
to the long axis of ducts as a continuous layer. The myo-
epithelial cells in TDLUs are discontinuous, stellate-shaped, 
and form a basket-like network around acini, allowing some 
luminal epithelial cells to directly contact the BM. Both epi-
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thelial and myoepithelial cells originate from the same pre-
cursor. This precursor cell niche is believed to hold the key 
to the definitive origin of both luminal epithelial and myo-
epithelial cells, as well as providing a possible cell popula-
tion for the origin of breast cancer [4].
Myoepithelial cells contain a large amount of micro-
filaments and smooth muscle-specific proteins such as al-
pha-actin and myosin that are responsible for the contrac-
tile function mediated by oxytocin during lactation. Each 
myoepithelial cell has long cytoplasmic processes that wrap 
around a secretory unit and hence, contraction of the myo-
epithelial cell can eject secretory product from the secretory 
unit into its duct. Thus, contraction is the most obvious and 
important function. Normal myoepithelial cells are critical 
for correct polarity of luminal epithelial cells, most likely via 
production of laminin-1 [5]. Adriance et al. showed that hu-
man breast luminal cells, when grown in three-dimensional 
type I collagen as opposed to laminin-rich gels, form struc-
tures with altered integrins that have reversed polarity and 
lack central lumina; however, if these same cells are cocul-
tured with myoepithelial cells in collagen I gels they exhibit 
correct apicobasal polarity [5]. On the other hand, Gudjons-
son et al. showed that myoepithelial cells present in invasive 
breast carcinoma have many similar features with normal 
myoepithelial cells but they show either complete absence 
or reduced expression of laminin-1. This one is strongly ex-
pressed around normal breast epithelial structures and thus 
tumor myoepithelial cells are unable to induce the polariza-
tion of luminal epithelial cells [4, 5].
Because breast cancer arises mainly in the luminal epi-
thelial compartment of the TDLU, until recently little atten-
tion has been paid to the surrounding myoepithelial cells 
[4]. However, progression to carcinoma involves alteration 
of the entire organized structure of the breast; depending 
on tumor grade, the changes can include the loss of polar-
ity, collapse of the glandular structure, disappearance of 
normal myoepithelial cells, and disruption of the BM at the 
epithelial–stromal border [7]. Myoepithelial cells form a 
natural border which is a semi-continuous protective sheet 
separating the human breast epithelium and the surround-
ing stroma. They suppress stromal invasion of tumor cells 
not only physically, but also by the secretion of various anti-
angiogenic and anti-invasive factors. Among these, maspin 
is one of the most important tumor suppressors that are se-
creted by myoepithelial cells. It is a member of the serpin 
family of serine proteases which inhibits tumorigenesis, tu-
mor cell migration and metastasic spread thus it functions 
as a tumor suppressor. Maspin is secreted in large quantities 
by the normal cells whereas tumor cells do not secrete it [5].
Myoepithelial cells regulate the flow of fluid and control 
the entry and exit of nutrients, electrolytes and other growth 
factors. They also process signals of endocrine or paracrine 
nature and perhaps act as an intermediary in such signal-
ing processes by passing information both inwards and 
outwards in a paracrine fashion. The disruption of this cell 
layer results in the release of the growth factors, angiogenic 
factors, reactive oxygen species that cause an alteration in 
the microenvironment and the loss of myoepithelial cells. 
BM is the distinctive key feature of invasive carcinoma, be-
cause most tumor epithelial cells have to first pass through 
the myoepithelial cell layer and then the BM in order to 
physically contact the stroma [5, 8]. It is also postulated and 
generally accepted that primary breast carcinomas show a 
dramatic increase in the ratio of luminal-to-myoepithelial 
cells, and that many invasive breast carcinomas essentially 
lack myoepithelial cells entirely [4]. It may be possible that 
the myoepithelial cells are degraded by the overproduction 
of the degradative enzymes or they are selectively eliminat-
ed by apoptosis [5, 8]. Myoepithelial cells rarely transform; 
however, when they do transform, they generally give rise to 
tumors of low malignancy [4].
We need to understand what prevents myoepithelial 
cells to exhibit the tumor suppressive properties. It is also 
possible that the tumor suppressive ability of myoepithe-
lial cells depends on their complete differentiation and that 
changes in their expression pattern can lead to reversal of 
their function, i.e., that undifferentiated myoepithelial cells 
may actually promote tumor progression instead of sup-
pressing it. These observations could open up the possibil-
ity of a future differentiation therapy where cancer cells are 
forced to differentiate along the myoepithelial pathway, thus 
manufacturing cells of lower malignancy or those that could 
suppress the aggressive behavior of their more malignant 
counterparts [4].
Confirmation of the myoepithelial cell layer on routine 
histology can be done with the help of alpha-smooth muscle 
actin (α-SMA)  immunostaining; however, these cells can 
also be identified by S-100, calponin, h-caldesmon, smooth 
muscle heavy chain (SMMHC) antibodies and CD10 [5]. 
Because of epithelial origin, they also express cytokeratins 
(CK) characteristic for the basal layer of stratified epithelia, 
such as CK 5, CK 14, and CK 17 [4].
Fibroblasts
Tumors are known as wounds that do not heal. This 
implies that cells that are involved in angiogenesis and the 
response to injury, such as endothelial cells and fibroblasts, 
have a prominent role in the progression, growth and spread 
of cancers [8]. Fibroblasts are cells that form the basic cel-
lular component of connective tissue and contribute to its 
structural integrity. They play important roles in wound 
healing, regulation of epithelial differentiation and inflam-
mation. In healthy organs, fibroblasts have a low prolifera-
tion index and minimum metabolic capacity. By contrast, 
during wound healing and in cancers, fibroblasts become 
activated, start to proliferate, secrete higher amounts of 
extracellular matrix (ECM) components, and acquire con-
tractile features. Fibroblasts from tumors are known as re-
active fibroblasts, peri-tumoral fibroblasts, myofibroblasts, 
tumor-associated or cancer-associated fibroblasts (CAFs) 
[3]. Characteristic feature of CAFs is expression of α-SMA 
and its expression is higher in fibroblasts derived from can-
cer tissues than in those derived from normal tissues [9].
Fibroblasts are associated with cancer cells at all stages 
of cancer progression, and their structural and functional 
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contributions to this process are beginning to emerge. 
Their production of growth factors, chemokines and ECM 
facilitates the angiogenic recruitment of endothelial cells 
and pericytes. Cancer cells tumoriginity was dramatically 
increased when inoculated with fibroblasts. Fibroblasts are 
therefore considered a key determinant in the malignant 
progression of cancer and represent an important target 
for cancer therapies [3, 10]. Normal fibroblasts maintain 
the extracellular environment through the production and 
remodeling of the ECM. CAFs have distinct characteristics 
and substantial data to support a role for CAFs in promoting 
tumor progression through morphological and phenotypic 
changes in various breast cancer subtype cells by production 
of TGF-β [8, 9]. In human breast tumors, the abundance 
of stromal CAFs is associated with aggressive adenocarci-
nomas and predicts human disease recurrence. In addition, 
CAFs have been shown to contribute to drug resistance and 
to reduce anti-tumor immunity [11].
The origin of CAFs has been actively investigated and 
multiple hypotheses have been proposed. One possibility 
is that they are derived from native interstitial fibroblasts 
whose phenotype has been modified by persistent aberrant 
signaling from neighboring tumor epithelial cells. Alterna-
tively, they can be differentiated from bone marrow-derived 
mesenchymal stem cells that are recruited to the tumor site 
via endocrine stimulation by tumor-derived factors [8].
CAFs often express α-SMA. These cells are also positive 
for vimentin and desmin, but do not express CKs, CD31 
and smooth muscle myosin [3].
Leucocytes
Immune cells are one of the most dynamic cell popula-
tions present within tumors and healing wounds and during 
the remodeling of breast tissue in pregnancy and involution. 
The smoldering inflammation was proposed as the seventh 
hallmark of cancer [1, 8]. High numbers of infiltrating leu-
kocytes are present in ductal carcinoma in situ (DCIS) with 
focal myoepithelial cell layer disruptions, suggesting that 
they might play a role in invasive progression [8]. 
Among leucocytes, tumor associated macrophages 
(TAMs) represent the vast majority, sometimes more than 
50%. Their importance should not be underestimated be-
cause they are able to control the immune response, cellular 
mobility and to stimulate/inhibit angiogenesis and lym-
phangiogenesis [12]. During chemically induced neoplastic 
transformation macrophages induce DNA damage through 
the release of reactive oxygen and nitrogen intermediates. 
Such macrophages have the potential to promote the sur-
vival of transformed cells and establish a state of chronic in-
flammation via secretion of the proinflammatory cytokines 
tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-1β 
[1]. Moreover, macrophages can modulate the drug resis-
tance and stimulate tumor regrowth by various substances 
secreted into the microenvironment. For example, irradia-
tion causes tumor necrosis, vascular damage, and hypoxia, 
which together or separately can induce the upregulation 
of several myeloid cells/monocytes chemoattractants, like 
vascular endothelial growth factor (VEGF) in the tumor 
microenvironment. De novo recruitment of myeloid cells 
drives tumor regrowth via their effects on the tumor blood 
vessels and, possibly, the cancer cells [12, 13].
Macrophages are highly heterogenic members of the 
mononuclear phagocyte system. They are distributed 
throughout every organ of the body and can ingest microbes 
and present antigens to T lymphocytes, therefore constitu-
ting a first line of defense against invading pathogens [1, 12]. 
In inflamed and remodeling tissues, elevated macrophage 
turnover is indefinitely supplied largely from hematopoietic 
progenitor cells (HPCs), which proliferate and differentiate 
into promonocytes in the bone marrow before they exit into 
the circulation as monocytes. This proliferation program is 
orchestrated through colony stimulating factor 1 (CSF1), 
a key growth factor regulating macrophage proliferation 
and survival, produced by the local tissue stroma. Mono-
cytes then undergo final differentiation into macrophages 
as they strain in the target tissues. Once resident in tissues, 
macrophages acquire a distinct, tissue-specific phenotype in 
response to signals present within individual microenviron-
ments. Depending on the microenvironmental signal type, 
macrophages can be polarized into “classical” (or M1) and 
“alternative” (or M2) phenotypes [1, 12, 14, 15].
During M1 activation, IFN-γ and other molecules are 
involved to bring a Th1 response, thus type I inflammation, 
intracellular pathogen killing and antitumor immunity. M2 
activation is known to accelerate tissue repair and tissue 
growth. These suggest that the increase of M1 macrophages 
in cancer is associated with less tumor aggressiveness, while 
M2 macrophages stimulate tumor growth and lead to poor 
prognosis [14, 16].
Various mouse studies have shown that monocytes are 
recruited into tumors in large numbers by chemokines se-
creted by both malignant and stromal cells. Upon mono-
cyte differentiation into TAMs, these cells support the pro-
liferation, survival, and motility of the cancer cells as well 
as angiogenesis; suppress antitumor immunity; support 
progression of cancer cells at the primary tumor site and 
extravasation/growth at distant metastatic sites. Previously, 
activated macrophages were believed to exhibit antitumor 
activity by directly attacking tumor cells in the tumor mi-
croenvironment. However, many recent studies have indi-
cated the protumoral functions of TAMs, and thus, TAMs 
are believed to be predominantly polarized in the tumor 
microenvironment toward an M2-like phenotype and that 
this underlies their ability to promote the growth and vas-
cularization of tumors. This is supported by expression of 
CD163 and CD204, a characteristic feature of M2 macro-
phages [12, 16]. Another typical markers of M2 macro-
phages are MRC1, TGM2, CD23, CCl22; M1 express CD64 
and CXCL10 markers [14].
TAMs are responsible for immune alterations in breast 
cancer. The first way is inhibition of antitumor T-cell re-
sponses by secreting anti-inflammatory cytokines, like 
IL-10. Other mechanisms are the recruitment of immu-
nosuppressive leucocytes and the inhibition of tumori-
cidal function by decreasing of MHC class II expression. 
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The main function of MHC class II molecules is to pre-
sent processed antigens, which are derived primarily from 
exogenous sources, to CD4+ T-lymphocytes. MHC class II 
molecules thereby are critical for the initiation of the anti-
gen-specific immune response [14, 17]. They are doing this 
to limit tissue damage due to deleterious inflammation. The 
continually activated macrophages undergo apoptosis or 
functionally ‘stand-down’, adopting an anti-inflammatory 
phenotype defined by the ability to suppress persistent im-
munity and facilitate wound healing [1].
Anatomically, macrophages are present at high numbers 
at the margins of mammary tumors with decreasing fre-
quency throughout the stroma moving in within the tumor. 
Within the tumor mass, macrophages, either individually or 
in clusters, are commonly found in association with blood 
vessels and orchestrate the migration of tumor cells [1].
Macrophages have emerged as an important key player 
in breast cancer progression and represent an attractive tar-
get for breast cancer therapy. Current interventions have fo-
cused on three strategies: blocking macrophage precursor 
recruitment, depletion of TAMs and their progenitors, and 
reprograming macrophage function within tumors [1].
Mast cells
Mast cells are granulated immune cells characterized 
by their cargo of inflammatory mediators, comprised of a 
wide array of preformed bioactive molecules stored in cy-
toplasmic granules, which are released upon encountering 
the appropriate stimuli and have beneficial roles in immu-
nological responses against pathogens, including intestinal 
helminths, bacteria, and viruses. Mast cell-derived media-
tors also participate in tissue physiological processes, such 
as wound healing and tissue repair, and in some pathologi-
cal conditions, such as immediate allergic reactions [18]. 
Human mast cells derive from CD34+, CD117+ pluripotent 
hematopoietic stem cells, which arise in the bone marrow. 
Mast cell progenitors enter the circulation and subsequently 
complete their maturation in tissues [19].
At least two major populations of mature mast cells have 
been described in humans based on their protease content. 
Mast cells containing only tryptase are termed MCT, while 
those containing tryptase, chymase, carboxypeptidase A, 
and cathepsin G are named MCTC. These mast cell subsets 
differ in their tissue localization; for instance, the MCTC is 
the predominant type found in normal skin and small bowel 
submucosa, whereas the MCT is almost the exclusive type 
found in small bowel mucosa and in bronchial/bronchiolar 
areas [18].
Back in 1992, Judah Folkman suggested that TAMs and 
mast cells play an important role in angio- and lymphan-
giogenesis [20]. Researchers have demonstrated that mast 
cells produce several proangiogenic (VEGF-A, VEGF-B, 
and FGF-2) and lymphangiogenic factors (VEGF-C and 
-D). In addition, it was shown that VEGFs are chemotactic 
for mast cells, indicating that mast cells are a target, in ad-
dition to be a source, for VEGF. Human mast cells produce 
different matrix metalloproteinases (e.g., MMP-9) and pro-
teases (tryptase and chymase), which regulate the digestion 
of ECM favoring the migration of cancer cells [19].
The role of mast cells in cancer is dual and uncertain. 
Some scholars highlight the anticancer function of mast 
cells. Human mast cells contain different proinflammatory 
mediators, but are unique in their ability to pre-store and re-
lease potentially beneficial anticancer mediators. For exam-
ple, human mast cells have pre-stored and released TNF-α 
within their granules. Furthermore, human mast cells re-
lease granulocyte-macrophage colony-stimulating factor 
(GM-CSF). Both TNF-α and GM-CSF have been used as 
anti-cancer agents. In this way, antitumor agents from mast 
cells could be used as a potential “Trojan Horse” of cancer 
cellular immunotherapy [21]. 
Xie et al. suggests that mast cells can induce prostate 
cancer chemotherapy and radiotherapy resistance by modu-
lation of p38/p53/p21 [19, 22]. Mast cells have a protumor 
action in human bladder cancer through stimulating estro-
gen receptor β (ERβ). In a murine model of bladder cancer, 
authors showed that a selective ERβ antagonist inhibited 
mast cell-promoted tumor growth [19, 23].
Some groups have concluded that the prognosis is worse 
with a higher density of mast cells in the breast cancer tis-
sue [24]. Xiang et al. have observed more numerous peri-
tumoral MCs in G3 breast cancers, increased tryptase be-
ing associated with higher tumor grade and more lymph 
node metastasis compared to lower grades. They have also 
noted that tryptase promotes the invasion and migration of 
breast cancer cells along with the activation of matrix metal-
loproteinase-2, and have concluded that tryptase promotes 
breast cancer migration and invasion [25]. Raica et al.  re-
vealed strong positive correlations between populations of 
MCs and lymphatic vessels in some molecular subtypes of 
breast cancer, thus supporting the idea of MCs involvement 
in metastasis by lymphangiogenesis [26]. Ribatti et al. have 
pointed out that angiogenesis increased in parallel with the 
number of tryptase-positive MCs particularly inside lymph 
nodes associated with micrometastases compared to non-
metastatic lymph nodes [27]. It has also been demonstrated 
that during breast cancer progression MCs may contribute 
to stromal remodeling and differentiation of myofibroblasts, 
through tryptase released in the stromal microenvironment 
[28]. All these mean that targeting MCs could be involved 
in the inhibition of angiogenesis, lymphangiogenesis and 
many other negative effects of MCs’ activation. Our research 
showed that mast cells dynamics is strongly influenced by 
hormone receptors and HER2 status. Mast cells from intra-
tumoral stroma increased in aggressive tumor types and is a 
worse prognostic factor [29].
Tissue microenvironment has profound effects on the 
progression of cancer cells by its paracrine signaling. Mo-
lecular characterization of various cell types from the nor-
mal breast tissue, DCIS and invasive breast tumor revealed 
significant changes in gene profile in all cell types during 
breast tumor progression. Microenvironment changes in-
fluence tumor progression as well as the efficacy of various 
cancer therapies [5]. There is compelling evidence that the 
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elements of tumor microenvironment respond to different 
stimuli and release distinct mediators, some antitumorige-
nic, while others protumorigenic activity [19].
Conclusions
In further researches it is necessary to unravel the factors 
determining the failure of breast stroma elements to exert 
anticancer functions. Even if a lot of things are known about 
breast cancer, the mortality is still high. Our findings suggest 
that cancer therapy should be an individual one, approved 
after complex diagnosis of the patient. Each of the known 
players of breast stroma involved in tumorigenesis and can-
cer progression can be influenced and directed towards an 
“anticancer” state. This could be the therapy of future.
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